ZBH Zimmer Biomet Holdings, Inc.

Look at the breakdown of Intuitive Surgical's revenue streams—Instruments and Accessories alone generate roughly 60% of the top line on a per-procedure basis. That tight link between surgery volume and cash flow explains why investors reacted so sharply when Intuitive noted in its fiscal Q2 2026 call that U.S. procedure growth had slowed. With recurring earnings visibility clouded, how much downside risk is the market actually pricing in.

Stryker's sales have grown about 10% a year on average over the past three years, and so have ResMed's. That shared growth rate in medical devices is the bet the two have in common. Stryker (SYK) is the giant, selling hospitals everything from hip and knee products to capital equipment. ResMed is a sleep device maker with less than a quarter of Stryker's revenue. Stryker costs 32.6 times its past year's earnings, against 21.9 times for ResMed. So does Stryker's reach justify that higher price? T

Zimmer Biomet currently trades at $91.50 per share and has shown little upside over the past six months, posting a middling return of 4.4%. The stock also fell short of the S&P 500’s 16.9% gain during that period.

Zimmer Biomet Holdings: recent performance and context Zimmer Biomet Holdings (ZBH) has drawn investor attention after a stretch of weaker share performance, with the stock down 1.3% over the past day and 10.5% over the past month. At a share price of US$89.69, Zimmer Biomet Holdings has seen momentum fade recently, with the 30-day share price return down 10.5% and the 1-year total shareholder return declining 6.5%. This points to cooler sentiment following earlier periods of...

Intuitive Surgical (ISRG) shares fell 10.4% in the past year, while the S&P 500 returned 16.5%. Much of the market has focused on moderating U.S. procedure growth. The more telling number is 144 trade-ins in fiscal Q2 2026, up from 83 a year earlier. Most came from customers moving to the new da Vinci 5 robot. Those trade-ins matter most if upgrades continue and each surgery also earns more. Is that number a blip, or are customers still trading up.

A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.

Intuitive Surgical is expanding robotic surgery in ASCs with lower-cost XiR systems, opening access to new customers and outpatient procedures.

Intuitive Surgical (ISRG) stock could climb 23.9% to the April high it last fell back from, and you would risk about 5% to find out. That looks like a surgical-robot leader on sale, but the price history disagrees. Over the last two years, none of its visits to this price range turned into a 20% gain before a 5% drop.

Intuitive Surgical (ISRG) has lost about 12% over the past year, while the S&P 500 returned about 17%. Most of the debate has been about the U.S. procedure growth slowing. The number that should worry a holder more is the money the company collects on the instruments used in each operation. Intuitive plans to lower it.

Intuitive Surgical (ISRG), maker of the da Vinci surgical robots, trades at about $382, some 36% below its 52-week high. Even so, you pay about 35.9 times trailing adjusted earnings. That is normalized net income with stock-based compensation added back, a basis meant to sit closer to the one analysts forecast on, though the two are not defined identically. Analysts' forecasts run to 2027, the year Intuitive plans to start lowering what customers pay per use on some instruments.

As Zimmer Biomet has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain cautious about the stock’s prospects.

Intuitive Surgical (ISRG) trades near $370, about 38% below its 52-week high, after growth in its US robotic-surgery procedures slowed. Selling a put pays you now for agreeing to buy the shares much lower, and you keep the payment either way. The catch is it only works if you would want this business at that price.

Zimmer Biomet Holdings, Inc. recently announced a major reshuffling of its leadership structure, effective October 1, 2026, promoting Gary Campbell to President, Americas; Brian Hatcher to President, Recon, S.E.T., CMFT, Neuro and Biosurgery; and Bradley Kessler to President, Americas – Robotics, Technology and Data, while Group President Kevin Thornal exited on September 30, 2026. This overhaul elevates long-tenured internal leaders with deep orthopedic, robotics and commercial experience,...

Reducing headcount at the Swiss site is part of an ongoing effort to simplify the company’s manufacturing footprint and supply chain.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

The company promoted three executives and eliminated a fourth position as part of changes intended to support its ongoing commercial transformation.

Intuitive Surgical (ISRG) has handed its owners a hard year. The stock is down 25% over the trailing twelve months while the S&P 500 returned 19.3%, and it now trades about 41% below its 52-week high. After a fall like that the natural hope is that the big moves are behind you. Options priced a year out say they are not.

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

In the world of robotic surgery, one company is both the undisputed leader and the most expensive option, forcing investors to ask if operational excellence is worth the premium.

This is a market-broadening year for Intuitive Surgical. The company is expanding beyond its core da Vinci systems to serve a wider continuum of hospitals and surgery centers.

While investors fixate on a slowdown in current procedures, hospitals are accelerating their investment in the company's core platform, revealing a crucial, under-appreciated strength.

With US procedure growth slowing and the shares well below their high, the operating margin has widened in each of the last three years.

ZBH's growth outlook is backed by healthy procedure demand and Z1, HAMMR and OrthoGrid adoption, though debt and competition remain concerns.

Zimmer Biomet Holdings has seen its share price decline about 27.9% over the past five years, yet the stock still screens as attractively priced on several valuation checks. This raises questions for investors trying to reconcile weak long term returns with a more positive current valuation read. Over the past five years the stock has declined about 27.9%, which signals that long term holders have not yet been rewarded despite the recent rebound. The ongoing shift to a fully dedicated sales...

ISRG's software roadmap is strengthening da Vinci 5, with new features, renewals and recurring service revenues reinforcing its digital ecosystem.

Stryker has gained 3.8% since March-end as Mako robotics, hospital capital demand and international growth drive momentum.

Zimmer Biomet has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Zimmer Biomet’s second quarter results were driven by strong execution in its hip franchise, robust technology sales, and progress in the U.S. sales force transformation. CEO Ivan Tornos highlighted that new product adoption, such as the Z1 hip stem and OrthoGrid navigation, contributed to above-average growth in the U.S. In addition, increased demand for the company’s technology and data solutions, including capital equipment sales, played a key role. Management attributed the quarter’s perform

Stryker's 13.6% three-month rally reflects stronger sales, margins and production, but execution risks and a premium peer valuation could test further gains.

Stryker's stronger growth, margin gains and product pipeline support the case, but cyber costs, supply constraints and acquisition execution keep risks elevated.

Stryker enters the second half with Q2 momentum restored, but meeting guidance hinges on production, backlog conversion and managing cyber and supply risks.

Get paid a real income now on your Intuitive Surgical shares—income you keep no matter what—in exchange for agreeing to sell at a higher price if the stock gets there.

Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years.

Management raised full-year guidance on strong hip and technology segment growth.

Zimmer Biomet (NYSE:ZBH) reported second-quarter 2026 net sales of $2.177 billion, up 4.8% on a reported basis and 4.0% on an organic constant-currency basis, as growth in hips, specialty businesses and technology helped offset weaker performance in certain other product lines. U.S. organic constan

Zimmer Biomet Holdings (ZBH) just paired stronger than expected quarterly results with a guidance increase, as management pointed to solid execution in U.S. hip and technology lines and progress in its sales force restructuring. See our latest analysis for Zimmer Biomet Holdings. Zimmer Biomet Holdings' recent guidance lift and Q2 beat come after a period of mixed returns, with the share price at US$97.19 and a 90-day share price return of 18.05%. However, the 5-year total shareholder return...

Zimmer Biomet Holdings is back in focus as analysts fine tune their price targets around recent research and earnings news. Targets such as US$110, US$95 and US$93 reflect a mix of supportive and cautious views on how the current share price lines up with execution and growth expectations. As you read on, you will see how these moves fit into the evolving narrative and what to watch next to stay on top of sentiment around Zimmer Biomet Holdings. Stay updated as the Fair Value for Zimmer...

Boston Scientific's 2026 guidance cut tests its recovery as WATCHMAN weakness, EP share losses and delayed margin gains push a broader rebound toward 2028.

The restructuring, intended to give Zimmer Biomet a fully dedicated sales force, is expected to be complete by the end of 2027.

Zimmer Biomet Holdings Inc (ZBH) raises full-year outlook on robust US hip and technology growth, while navigating ongoing commercial transformation and international headwinds.

Moby summary of Zimmer Biomet Holdings, Inc.'s Q2 2026 earnings call

Zimmer released its Q2 financials ahead of market open, prompting its shares on the New York Stock Exchange to rise by over 5% at market open on 5 August.

ZBH beats second-quarter earnings and revenue estimates, raises its 2026 outlook and gains in pre-market despite pressure on adjusted margins.

While the top- and bottom-line numbers for Zimmer (ZBH) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zimmer Biomet Holdings (NYSE:ZBH) reported better-than-expected second-quarter results and increased its guidance for the full year, helping lift the medical technology company’s shares more than 4% in pre-market trading. The company posted adjusted earnings of $2.

Zimmer (ZBH) delivered earnings and revenue surprises of +2.99% and +2.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medical device company Zimmer Biomet (NYSE:ZBH) announced better-than-expected revenue in Q2 CY2026, with sales up 4.8% year on year to $2.18 billion. Its non-GAAP profit of $2.07 per share was 3% above analysts’ consensus estimates.